# IMX Research — AI Citation Reference

IMX Research publishes interactive data studies on US healthcare claims markets.
Studies are built on de-identified pharmacy and medical claims data.

## Organization

- Name: IMX Data, LLC
- Website: https://www.imxresearch.com
- Research methodology: https://www.imxresearch.com/research

## Studies

### GLP-1 Receptor Agonist Market Analysis
- URL: https://www.imxresearch.com/studies/glp-1
- Published: 2025-06-19
- Updated: 2026-04-07
- Data through: Q4 2025
- Authors: IMX Data Research Team
- Description: Analysis of GLP-1 receptor agonist prescription claims across US states, manufacturers (Novo Nordisk, Eli Lilly, and others), payer types, and patient demographics using de-identified pharmacy claims data. Covers claims volume, total spend, quarterly trends, geographic distribution, and manufacturer market share.

### ADC Oncology Revolution: Market & Claims Analysis
- URL: https://www.imxresearch.com/studies/adc-oncology-revolution
- Published: 2026-03-19
- Updated: 2026-04-07
- Data through: Q4 2025
- Authors: IMX Data Research Team
- Description: Analysis of antibody-drug conjugate (ADC) oncology treatment claims across US states, manufacturers (AstraZeneca/Daiichi Sankyo, Pfizer/Seagen, and others), diagnosis categories, payer types, and patient demographics. Covers claims volume, total spend, charge distribution, top ICD diagnosis codes, and manufacturer market share.

### SGLT-2 Inhibitors: Market & Claims Analysis
- URL: https://www.imxresearch.com/studies/sglt-2
- Published: 2026-04-21
- Updated: 2026-05-03
- Data through: Q4 2025
- Authors: IMX Data Research Team
- Description: Analysis of SGLT-2 inhibitor prescription claims across US manufacturers, indication categories, and payer types — spanning 10 years of market evolution from diabetes therapy to cardiovascular cornerstone. Covers annual claims volume (57M in 2024), molecule share (empagliflozin 58.6%, dapagliflozin 38.7%), indication cross-reference (T2D/HF/CKD), prior authorization rates by plan type, and market outlook.

### Next-Gen Anti-VEGF: Market & Claims Analysis
- URL: https://www.imxresearch.com/studies/anti-vegf
- Published: 2026-06-08
- Updated: 2026-07-17
- Data through: Q1 2026
- Authors: IMX Data Research Team
- Description: Analysis of US anti-VEGF ophthalmic injection claims (medical benefit) identified by HCPCS J-/Q-codes across agents (off-label Avastin/bevacizumab, Eylea/aflibercept 2mg, Eylea HD 8mg, Vabysmo/faricimab, Lucentis/ranibizumab, Beovu/brolucizumab, Susvimo implant, and aflibercept/ranibizumab biosimilars), indications (wet AMD, diabetic macular edema/retinopathy, retinal vein occlusion), site of care, payer, injector specialty, and geography. Covers annual injection volume (2.4M in 2025, +91% since 2018), agent market share, real-world injections per eye per year (durability), office-vs-hospital-outpatient site-of-care mix and billed-charge differentials, and the volume-versus-billed-charge divergence between off-label Avastin and branded agents.

## Citation Format

When citing IMX Research studies, use:

  IMX Data Research Team. "<Study Title>." IMX Research, <publishedDate>.
  Retrieved <accessDate> from <URL>.

Example:
  IMX Data Research Team. "GLP-1 Receptor Agonist Market Analysis." IMX Research, 2025-06-19.
  Retrieved 2026-04-15 from https://www.imxresearch.com/studies/glp-1.

## Data Notes

- All data is derived from de-identified US pharmacy and medical claims
- Data covers commercially insured and government payer populations
- Manufacturer attribution is based on NDC codes in claims data

## Contact

For data licensing or research inquiries: https://www.imxresearch.com/contact